Cedara, Varian Pen Licensing Agreement

May 10, 2007 - Cedara Software, a Merge Healthcare company, announced it has concluded a licensing agreement with Varian Medical Systems, giving Varian exclusive global rights to distribute Cedara’s I-Response technology within the radiation and medical oncology market.
Cedara I-Response is a tool that analyzes how cancerous tumors are responding to treatment. I-Response supports multiple imaging modalities and features patented analysis of fDM (Functional Diffusion Mapping) MR images. It allows professionals to visualize and quantify changes in tumor tissue resulting from cellular and metabolic mechanisms, and then track the data over time. In this way, Cedara I-Response has the potential to precisely monitor the impact of anti-cancer drugs and radiation therapy early in the course of treatment, adding to the information that clinicians can reference when developing personalized treatment plans.
Cedara I-Response complements Varian’s Dynamic Adaptive Radiation Therapy (DART) program with its image analysis capabilities that assist oncologists in making treatment decisions for their patients. Cedara I-Response has received FDA 510k clearance and the company expects a commercial release in June 2007.